Bryn Mawr Capital Management’s GSK GSK Stock Holding History

Bryn Mawr Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,258	Closed	-$227K	–	90
2019 Q3	$227K	Hold	4,258	–	–	0.19%	76
2019 Q2	$213K	Hold	4,258	–	–	0.18%	79
2019 Q1	$222K	Sell	4,258 -58	-1%	-$2.9K	0.2%	76
2018 Q4	$206K	Sell	4,316 -136	-3%	-$6.7K	0.19%	69
2018 Q3	$224K	Hold	4,452	–	–	0.19%	77
2018 Q2	$224K	Hold	4,452	–	–	0.2%	72
2018 Q1	$217K	Buy	+4,452	New	+$207K	0.2%	68

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bryn Mawr Capital Management's GSK Position: Q4 2019 in Review

Bryn Mawr Capital Management sold out of GSK (GSK) in Q4 2019, closing a stake of 4,258 shares — an estimated $227K sold.

Bryn Mawr Capital Management first reported a position in GSK in Q1 2018 and held it in 7 quarters. The position peaked at $227K in Q3 2019. 894 funds tracked by Wall St. Rank hold GSK as of Q4 2019.

Bryn Mawr Capital Management reported no remaining GSK position as of Q4 2019 after selling out during the quarter.
Bryn Mawr Capital Management sold 4,258 GSK shares in Q4 2019, an estimated $227K.
Bryn Mawr Capital Management first reported a position in GSK in Q1 2018 and held it in 7 quarters.
Bryn Mawr Capital Management's GSK position peaked at $227K in Q3 2019.
894 funds tracked by Wall St. Rank held GSK as of Q4 2019.

Based on Bryn Mawr Capital Management's 13F filing for Q4 2019, filed 31 Jan 2020.